(Q38851434)
Statements
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials (English)
R M Savic
M Weiner
W R MacKenzie
M Engle
W C Whitworth
J L Johnson
P Nsubuga
N V Nguyen
C A Peloquin
K E Dooley
S E Dorman
Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention
1 reference